Samsung BioLogics said on June 21 products manufactured from its production line here won approval from the Canadian drug authority.
The Korean pharmaceutical company said Health Canada granted approval permitting Samsung BioLogics to sell products produced from its factory, located in Songdo, west of Seoul, in the Canadian market.
The affiliate of Samsung Group said the approval is significant as the United States and Canada account for roughly 60 percent of the world‘s market for biopharmaceutical products.
The company also earlier received similar permission from the European Medicines Agency regarding the products made from the Songdo factory.
Samsung BioLogics expressed its thanks for the approvals and for being now able to supply products to clients stably and in a timely manner.
By Song Seung-hyun and newswires (firstname.lastname@example.org